NCT05229562View on ClinicalTrials.gov

A Study to See How BIIB122 Works in the Human Body, and to Evaluate it's Safety, and Tolerability in Healthy Adult Japanese, Chinese, and Caucasian Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

February 17, 2022

Primary Completion Date

September 7, 2022

Study Completion Date

September 7, 2022

Conditions
Healthy Volunteer
Interventions
DRUG

BIIB122

Administered as specified in the treatment arm.

Trial Locations (1)

92801

Anaheim Clinical Trials, LLC, Anaheim

Sponsors

Lead Sponsor

Biogen
All Listed Sponsors
lead

Biogen

INDUSTRY

NCT05229562 - A Study to See How BIIB122 Works in the Human Body, and to Evaluate it's Safety, and Tolerability in Healthy Adult Japanese, Chinese, and Caucasian Participants | Biotech Hunter | Biotech Hunter